---
run_id: halo-evidence-vs-diagnosis-validation-v11-famous-sources-supplied-02
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
model_condition: famous_sources_supplied
run_number: 2
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 1024
seed: 202
prompt_source: condition packet (famous_sources_supplied) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 18fa1d51f6167dbbf1f7ece676734d5cdb459384bca25e1508dd96cd4745e42d
source_packet: a name-level list of famous source titles and authors, then the frozen Advisor prompt; no claims, summaries, source cards, or tension card - see run-packet.md
source_packet_sha256: 5f0d18f3e982d60319cdf56d83f5bfcb60ca486dc8eccd9dfcda42bea551750c
condition_packet_sha256: 5f0d18f3e982d60319cdf56d83f5bfcb60ca486dc8eccd9dfcda42bea551750c
output_file: model-outputs/famous_sources_supplied-02.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - famous_sources_supplied (run 02)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v11-v1`, condition `famous_sources_supplied`, run 2 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 202, on the frozen condition packet.

## Output

**Recommendation:** Run the Claim File Review.

**Why:**
Your current success is an "entangled" signal. You have positive lagging indicators (bookings, renewals) that are likely confounded by financial incentives (bundle pricing) and sales narratives (roadmap promises). More concerningly, your leading indicators—usage and support tickets—are misleading. High usage is driven by managers (non-users) rather than adjusters (users), and a drop in "wrong recommendation" tickets is likely a reporting artifact of users switching to training channels.

The Claim File Review is the only proposal that addresses the "ground truth" of the product's value proposition. By analyzing actual claim files, you can determine if SignalPath is solving the core problem or if adjusters are simply performing "security theater" for their managers. This is particularly critical for the regulated health-liability segment, where "explainability" is a hard constraint. Without knowing if the product actually works at the file level, scaling broadly is a gamble on sales momentum, and the Usage Quality Sprint is merely measuring the frequency of a potentially broken habit.

**The strongest reason against it:**
It is a slow, manual, and qualitative process that provides a small sample size. Unlike the Commercial Cleanroom or Usage Quality Sprint, it does not provide immediate "hard" financial or behavioral data that the board typically prefers during budget lockdowns. It risks identifying a fundamental product flaw (e.g., lack of explainability) too late to pivot the roadmap before the budget is locked.

**Observable evidence that would change my mind:**
If the "Commercial Cleanroom" data were available immediately and showed that accounts without the roadmap pitch and bundle pricing still renewed at the same rate as those with them. This would prove that the perceived value is intrinsic to the current product and not a result of sales engineering, making "Scale SignalPath Broadly" the logical choice.
